Clinical, laboratory, and hematologic findings in 21 PNH patients
| Case no. . | Age/sex . | WBC, × 109/L . | Neutrophil count, × 109/L . | Hb, g/dL . | Reticulocyte count, × 109/L . | PLT, × 109/L . | LDH, IU/L . | Flow cytometry of erythrocytes (CD59), % . | Flow cytometry of granulocytes (CD16b), % . | Duration of illness, mo . | Treatment/transfusion requirement . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pos* . | Int* . | Neg* . | Neg* . | ||||||||||
| 1 | 54/M | 2.9 | 1.769 | 15.6 | 100 | 55 | 800 | 96.9 | 0 | 3.1 | 12.8 | 92 | A/− |
| 2 | 60/M | 5.5 | 2.200 | 15.7 | 77 | 149 | 361 | 65.6 | 25.8 | 8.6 | 12.3 | 270 | P/− |
| 3† | 55/M | 6.5 | 4.160 | 13.5 | 98 | 156 | 673 | 90.7 | 0 | 9.3 | 3.0 | 180 | P/− |
| 4 | 27/M | 3.4 | 2.584 | 14.2 | 91 | 147 | 386 | 88.2 | 0 | 11.8 | 2.1 | 31 | ATG, Cy, G → P/− |
| 5 | 57/M | 6.4 | 3.712 | 11.4 | 108 | 183 | 1183 | 15.1 | 67.9 | 17.0 | 92.3 | 203 | P/+ |
| 6† | 35/F | 4.9 | 2.744 | 15.5 | 69 | 170 | 818 | 92.9 | 0 | 7.1 | 10.4 | 54 | A/− |
| 7 | 53/M | 3.2 | 1.088 | 10.8 | 153 | 98 | 2713 | 34.2 | 32.7 | 33.1 | 55.8 | 20 | P, continuous iron/+ |
| 8 | 82/M | 2.2 | 0.570 | 9.6 | 84 | 50 | 2028 | 1.7 | 89.4 | 8.9 | 62.7 | 254 | Intermittent iron/− |
| 9 | 52/F | 1.4 | 0.392 | 7.0 | 227 | 178 | 6070 | 68.7 | 0 | 31.3 | 89.3 | 115 | P → None/+ |
| 10 | 70/M | 3.1 | 1.612 | 9.4 | 104 | 269 | 1033 | 13.1 | 0 | 86.9 | 94.4 | 168 | A/+ |
| 11 | 29/F | 6.0 | 5.220 | 5.5 | 126 | 194 | 3094 | 61.6 | 9.8 | 28.6 | 95.0 | 114 | P/− |
| 12 | 20/M | 3.3 | 0.875 | 14.0 | 93 | 112 | 548 | 93.4 | 0 | 6.6 | 97.9 | 52 | A/− |
| 13† | 69/F | 3.1 | 0.992 | 11.1 | 75 | 52 | 995 | 85.5 | 0 | 14.5 | 37.4 | 164 | A/− |
| 14 | 23/F | 3.5 | 1.785 | 9.8 | 83 | 152 | 953 | 86.1 | 0 | 13.9 | 51.2 | 5 | None/− |
| 15 | 20/M | 4.1 | 3.034 | 7.9 | 108 | 106 | 2653 | 27.0 | 37.6 | 35.4 | 83.6 | 10 | None/− |
| 16† | 59/M | 2.8 | 1.064 | 12.7 | 44 | 54 | 348 | 96.5 | 0 | 3.5 | 3.5 | 0 | A/− |
| 17† | 71/M | 1.2 | 0.216 | 6.9 | 20 | 144 | 368 | 98.6 | 0 | 1.4 | 97.1 | 0 | None/− |
| 18† | 56/M | 2.6 | 1.612 | 9.9 | 205 | 56 | 3770 | 30.7 | 30.7 | 38.5 | 98.6 | 198 | P, continuous iron/− |
| 19† | 59/F | 2.4 | 1.944 | 5.6 | 24 | 13 | 558 | 88.4 | 0 | 11.6 | 11.6 | 0 | ATG, Cy, G → Cy, G, A+/− |
| 20 | 71/F | 9.2 | 6.656 | 10.1 | 261 | 126 | 1218 | < 1.0 | 99.6 | < 1.0 | 98.3 | 5 | P/− |
| 21 | 46/M | 2.4 | 0.936 | 13.1 | 74 | 96 | 1054 | 91.6 | 0 | 8.4 | 98.9 | 8 | None/− |
| Case no. . | Age/sex . | WBC, × 109/L . | Neutrophil count, × 109/L . | Hb, g/dL . | Reticulocyte count, × 109/L . | PLT, × 109/L . | LDH, IU/L . | Flow cytometry of erythrocytes (CD59), % . | Flow cytometry of granulocytes (CD16b), % . | Duration of illness, mo . | Treatment/transfusion requirement . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pos* . | Int* . | Neg* . | Neg* . | ||||||||||
| 1 | 54/M | 2.9 | 1.769 | 15.6 | 100 | 55 | 800 | 96.9 | 0 | 3.1 | 12.8 | 92 | A/− |
| 2 | 60/M | 5.5 | 2.200 | 15.7 | 77 | 149 | 361 | 65.6 | 25.8 | 8.6 | 12.3 | 270 | P/− |
| 3† | 55/M | 6.5 | 4.160 | 13.5 | 98 | 156 | 673 | 90.7 | 0 | 9.3 | 3.0 | 180 | P/− |
| 4 | 27/M | 3.4 | 2.584 | 14.2 | 91 | 147 | 386 | 88.2 | 0 | 11.8 | 2.1 | 31 | ATG, Cy, G → P/− |
| 5 | 57/M | 6.4 | 3.712 | 11.4 | 108 | 183 | 1183 | 15.1 | 67.9 | 17.0 | 92.3 | 203 | P/+ |
| 6† | 35/F | 4.9 | 2.744 | 15.5 | 69 | 170 | 818 | 92.9 | 0 | 7.1 | 10.4 | 54 | A/− |
| 7 | 53/M | 3.2 | 1.088 | 10.8 | 153 | 98 | 2713 | 34.2 | 32.7 | 33.1 | 55.8 | 20 | P, continuous iron/+ |
| 8 | 82/M | 2.2 | 0.570 | 9.6 | 84 | 50 | 2028 | 1.7 | 89.4 | 8.9 | 62.7 | 254 | Intermittent iron/− |
| 9 | 52/F | 1.4 | 0.392 | 7.0 | 227 | 178 | 6070 | 68.7 | 0 | 31.3 | 89.3 | 115 | P → None/+ |
| 10 | 70/M | 3.1 | 1.612 | 9.4 | 104 | 269 | 1033 | 13.1 | 0 | 86.9 | 94.4 | 168 | A/+ |
| 11 | 29/F | 6.0 | 5.220 | 5.5 | 126 | 194 | 3094 | 61.6 | 9.8 | 28.6 | 95.0 | 114 | P/− |
| 12 | 20/M | 3.3 | 0.875 | 14.0 | 93 | 112 | 548 | 93.4 | 0 | 6.6 | 97.9 | 52 | A/− |
| 13† | 69/F | 3.1 | 0.992 | 11.1 | 75 | 52 | 995 | 85.5 | 0 | 14.5 | 37.4 | 164 | A/− |
| 14 | 23/F | 3.5 | 1.785 | 9.8 | 83 | 152 | 953 | 86.1 | 0 | 13.9 | 51.2 | 5 | None/− |
| 15 | 20/M | 4.1 | 3.034 | 7.9 | 108 | 106 | 2653 | 27.0 | 37.6 | 35.4 | 83.6 | 10 | None/− |
| 16† | 59/M | 2.8 | 1.064 | 12.7 | 44 | 54 | 348 | 96.5 | 0 | 3.5 | 3.5 | 0 | A/− |
| 17† | 71/M | 1.2 | 0.216 | 6.9 | 20 | 144 | 368 | 98.6 | 0 | 1.4 | 97.1 | 0 | None/− |
| 18† | 56/M | 2.6 | 1.612 | 9.9 | 205 | 56 | 3770 | 30.7 | 30.7 | 38.5 | 98.6 | 198 | P, continuous iron/− |
| 19† | 59/F | 2.4 | 1.944 | 5.6 | 24 | 13 | 558 | 88.4 | 0 | 11.6 | 11.6 | 0 | ATG, Cy, G → Cy, G, A+/− |
| 20 | 71/F | 9.2 | 6.656 | 10.1 | 261 | 126 | 1218 | < 1.0 | 99.6 | < 1.0 | 98.3 | 5 | P/− |
| 21 | 46/M | 2.4 | 0.936 | 13.1 | 74 | 96 | 1054 | 91.6 | 0 | 8.4 | 98.9 | 8 | None/− |
WBC indicates white blood cell count; Hb, hemoglobin concentration; PLT, platelet count; LDH, lactate dehydrogenase; A, androgens; P, prednisolone; ATG, antithymocyte globulin; Cy, cyclosporine; G, granulocyte colony-stimulating factor.
Pos, Int, and Neg refer to positive, intermediate, and negative populations by single-color flow cytometric analysis of erythrocytes or granulocytes using CD59 or CD16b monoclonal antibody, respectively.
Includes AA-PNH syndrome.